[go: up one dir, main page]

NO20082923L - Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni - Google Patents

Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni

Info

Publication number
NO20082923L
NO20082923L NO20082923A NO20082923A NO20082923L NO 20082923 L NO20082923 L NO 20082923L NO 20082923 A NO20082923 A NO 20082923A NO 20082923 A NO20082923 A NO 20082923A NO 20082923 L NO20082923 L NO 20082923L
Authority
NO
Norway
Prior art keywords
schizophrenia
negative symptoms
antagonist
side effects
combination
Prior art date
Application number
NO20082923A
Other languages
English (en)
Norwegian (no)
Inventor
Mark Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20082923L publication Critical patent/NO20082923L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20082923A 2005-12-08 2008-06-25 Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni NO20082923L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08
PCT/US2006/046547 WO2007067617A2 (en) 2005-12-08 2006-12-07 Use of a cb1 antagonist for treating negative symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
NO20082923L true NO20082923L (no) 2008-09-02

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082923A NO20082923L (no) 2005-12-08 2008-06-25 Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2700974A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
HRP20131168T1 (hr) * 2007-12-18 2014-01-03 Sanofi Derivati azetidina, njihovo dobivanje i njihova terapijska primjena
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
US10266526B2 (en) * 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
JP3939744B2 (ja) * 2003-06-11 2007-07-04 メルク エンド カムパニー インコーポレーテッド 置換３−アルキルおよび３−アルケニルアゼチジン誘導体
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
CN101321523A (zh) 2008-12-10
DOP2006000273A (es) 2007-10-15
ECSP088505A (es) 2008-08-29
BRPI0619541A2 (pt) 2011-10-04
WO2007067617A3 (en) 2007-11-01
IL191888A0 (en) 2009-08-03
TNSN08205A1 (en) 2009-10-30
US20080221078A1 (en) 2008-09-11
WO2007067617A2 (en) 2007-06-14
CR9957A (es) 2008-09-22
AR056846A1 (es) 2007-10-24
ZA200803924B (en) 2009-10-28
TW200803839A (en) 2008-01-16
UY29995A1 (es) 2007-07-31
CA2632673A1 (en) 2007-06-14
MA30090B1 (fr) 2008-12-01
JP2009518423A (ja) 2009-05-07
RU2008127491A (ru) 2010-01-20
PE20071092A1 (es) 2007-12-10
AU2006321907A1 (en) 2007-06-14
KR20080073737A (ko) 2008-08-11
SV2008002929A (es) 2009-12-02
EP1962834A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
TNSN07376A1 (en) Npy antagonists, preparation and use
WO2007087468A3 (en) Adiponectin for treatment of various disorders
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
CL2010001173A1 (es) Compuestos derivados de 1,4-diazepam sustituido, antagonistas de ox1 y ox2; utiles para preparar un medicamento destinado al tratamiento o prevencion de un trastorno del sueño,para potenciar la calidad del sueno,y para tratar o controlar la obesidad.(divisional de la sol.n 3441-07)
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
UA92914C2 (ru) Гетероциклические соединения как положительные аллостерические модуляторы метаботропных глутаматных рецепторов
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
MX2010004875A (es) Derivados de tiazol y metodos para utilizarlos.
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
NO20083838L (no) Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
MX2009001315A (es) Compuestos de dimetilciclobutilo substituidos, su preparación y uso en medicamentos.
NO20063856L (no) Behandling av psykoser med quetiapin-antipsykotiske midler
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
WO2009067607A3 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application